[HTML][HTML] Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Abstract Background Checkpoint inhibitors (CPIs) have revolutionized the treatment of
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …
[HTML][HTML] Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
H Safa, DH Johnson, VA Trinh, TE Rodgers… - … for immunotherapy of …, 2019 - Springer
Background Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune
checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is …
checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …
[HTML][HTML] Structure-based classification predicts drug response in EGFR-mutant NSCLC
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
[HTML][HTML] Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
[HTML][HTML] Inhibition of the CD47-SIRPα axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data
CD47-SIRPα interaction acts as a “don't eat me” signal and is exploited by cancer to
downregulate innate and adaptive immune surveillance. There has been intense interest to …
downregulate innate and adaptive immune surveillance. There has been intense interest to …
[HTML][HTML] Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial
MS Kies, FC Holsinger, JJ Lee… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose To determine the potential efficacy of combining cetuximab with chemotherapy in
patients with advanced nodal disease, we conducted a phase II trial with induction …
patients with advanced nodal disease, we conducted a phase II trial with induction …
The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer
WS Samowitz, K Curtin, HH Lin, MA Robertson… - Gastroenterology, 2001 - Elsevier
Background & Aims: Estimates of the frequency of hereditary nonpolyposis colon cancer
(HNPCC) based on clinical criteria have varied widely. Recent studies of germline mismatch …
(HNPCC) based on clinical criteria have varied widely. Recent studies of germline mismatch …
Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): scale development and validation
KA Hutcheson, MP Barrow, DA Barringer, JK Knott… - Cancer, 2017 - Wiley Online Library
BACKGROUND The National Cancer Institute's Common Terminology Criteria for Adverse
Events (CTCAE) is the universal framework for toxicity reporting in oncology trials. The …
Events (CTCAE) is the universal framework for toxicity reporting in oncology trials. The …
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR …
T Cascone, WN William, A Weissferdt, HY Lin… - 2019 - ascopubs.org
8504 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major
pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of …
pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of …